Latest Articles

Publication Date
Safety of 48 months of elagolix with add-back therapy for endometriosis-associated pain.

Elagolix (ELA) 200 mg twice daily is an oral treatment approved for moderate-to-severe endometriosis-associated pain. However, the clinical use of ELA is limited by potential hypoestrogenic effects, including the loss …

Published: Nov. 7, 2025, midnight
Psychosocial Factors and Disease Localization as Independent Predictors of Sexual Dysfunction in Women with Endometriosis.

Background: This study examines the impact of endometriosis on sexual function, focusing on disease localization, pain severity, and psychosocial factors. It integrates the rASRM and Enzian classification systems to explore …

Published: Nov. 2, 2025, midnight
Potency of oral gonadotropin-releasing hormone antagonist as endometriosis-associated pain novel treatments: An updated meta-analysis of randomized controlled trials.

Elagolix, Linzagolix, and Relugolix, as oral gonadotropin-releasing hormone antagonists, have emerged as promising treatments for endometriosis-associated pain.

Published: Nov. 1, 2025, midnight
Diagnostic Delays and Economic Burden in Japanese Women with Endometriosis: A Cross-Sectional Analysis.

This study investigates the association between diagnostic delay (DD) and clinical and behavioral variables among Japanese women with endometriosis, and explores an optimal cut-off point distinguishing short and long DD.

Published: Oct. 25, 2025, midnight
Catamenial Pneumothorax Without Thoracic Endometriosis: A Case Report From the Gulf Cooperation Council (GCC) Region.

Catamenial pneumothorax is a rare clinical condition first described over seven decades ago. It typically occurs within 72 hours before or after menstruation and is most frequently observed in women …

Published: Oct. 18, 2025, midnight
Understanding Peritoneal Fluid Estrogen and Progesterone Concentrations Permits Individualization of Medical Treatment of Endometriosis-Associated Pain with Lower Doses, Especially in Adolescents Not Requiring Contraception.

Objectives: The aim of this study was to review the importance of peritoneal fluid steroid hormone concentrations to understand the mechanism of hormonal medical treatment of endometriosis-associated pain. Design: The …

Published: Oct. 12, 2025, midnight
Progestagens for pain symptoms associated with endometriosis.

Endometriosis is a hormone-sensitive inflammatory condition affecting between 5% and 10% of reproductive-aged women and an unknown number of gender-diverse individuals. It is often associated with debilitating pelvic pain symptoms. …

Published: Oct. 9, 2025, midnight
Comparison of the short-term effects of dienogest and oral contraceptives on pain and quality of life in women with endometriosis: a systematic review and meta-analysis.

To compare the short-term effects of dienogest and oral contraceptives (OCPs) on pain and quality of life in women with endometriosis.

Published: Oct. 9, 2025, midnight
Endometriosis-related infertility in China: analysis of the global burden of disease study 2021.

Utilizing the Global Burden of Disease (GBD) 2021 dataset, this study analyzed temporal trends (1990-2021) and age-period-cohort patterns of endometriosis-related infertility burden in China versus globally. By employing joinpoint regression …

Published: Oct. 7, 2025, midnight
Deep pelvic endometriosis: clinical features, diagnosis, and treatment - a comprehensive review.

Deep infiltrative endometriosis (DIE) is characterized by the infiltration of endometrial tissue into the pelvic organs, such as the rectovaginal septum, utero-ovarian, and uterosacral ligaments. Bowel involvement occurs in approximately …

Published: Sept. 30, 2025, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!